← Back to Clinical Trials
Recruiting NCT05638841

NCT05638841 Prospective Cohort Study of the Risk of Recurrent Atrial Fibrillation After Radiofrequency Ablation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05638841
Status Recruiting
Phase
Sponsor Peking University Third Hospital
Condition Atrial Fibrillation
Study Type OBSERVATIONAL
Enrollment 300 participants
Start Date 2023-01-01
Primary Completion 2024-12-31

Trial Parameters

Condition Atrial Fibrillation
Sponsor Peking University Third Hospital
Study Type OBSERVATIONAL
Phase N/A
Enrollment 300
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2023-01-01
Completion 2024-12-31
Interventions
After radiofrequency ablation of atrial fibrillation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

In this study, the continuous inclusion of atrial fibrillation patients treated by catheter ablation in the Department of Cardiology, Peking University Third Hospital, through the collection of clinical data and outpatient follow-up, to explore the risk factors of atrial fibrillation recurrence after catheter ablation and the influencing factors of major clinical events in atrial fibrillation patients, and further guide the management mode of atrial fibrillation patients.

Eligibility Criteria

Inclusion Criteria: * 1\) Age \> 18 * 2\) ECG or holter electrocardiogram confirmed atrial fibrillation Exclusion Criteria: * 1\) Hematological diseases, autoimmune diseases and malignant tumors * 2\) Immobility caused by hemiplegia or severe trauma * 3\) The expected survival time is less than 2 years * 4\) Poor compliance and high risk of expected loss of follow-up * 5\) Disorders of consciousness or Alzheimer's disease

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology